Drug Profile
Tagraxofusp - Stemline Therapeutics
Alternative Names: Diphtheria-toxin-interleukin-3-fusion-protein; DT(388)IL3; DT-388-IL-3; DT-IL-3; ELZONRIS; Elzonris; NS-401; SL-401; tagraxofusp-erzsLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Scott & White Healthcare; Texas A&M University
- Developer Dana-Farber Cancer Institute; Nippon Shinyaku; Stemline Therapeutics
- Class Antineoplastics; Bacterial toxins; Immunotoxins; Interleukins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Peptide elongation factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Blastic plasmacytoid dendritic cell neoplasm
- Phase II Acute myeloid leukaemia; Myeloproliferative disorders
- Phase I/II Multiple myeloma; Myelodysplastic syndromes
- No development reported Hairy cell leukaemia; Systemic scleroderma
Most Recent Events
- 13 Mar 2024 Stemline Therapeutics and Jonsson Comprehensive Cancer Center withdraws a phase-I trial in Acute myeloid leukaemia (Monotherapy, Combination therapy) prior to enrolment in the US (IV) (NCT05720988)
- 09 Dec 2023 Efficacy and adverse events data from phase I/II trial in Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem 2023)
- 09 Dec 2023 Pharmacodynamics data from a preclinical studies in acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition(ASH-2023)